Latest Administration News

Cambium Bio has cleared key regulatory hurdles for its lead dry eye disease treatment, Elate Ocular, and strengthened its balance sheet with a $2.12 million placement to support upcoming Phase 3 trials.

Fintech Chain Limited reported a mixed quarter with strong customer receipts and new IoT SaaS product launch, while finalising its ASX delisting. The company’s cash position tightened amid loan repayments and rising operating costs.

Domino’s Pizza Enterprises has explained the late filing of a director interest notice as an administrative oversight, reaffirming its compliance procedures amid ASX scrutiny.

Hydralyte USA reported an 8.5% rise in Q2 FY25 net sales, driven by strong May performance and improved margins, while preparing to launch new brain and gut health products.

C29 Metals has announced its strategic exit from Kazakhstan to concentrate on advancing its Australian copper and gold projects, notably the Mayfield site, with $1.05 million cash in hand.

InteliCare Holdings reported a $564,000 operating cash outflow in Q4 2025 and has secured $1 million in additional funding to support ongoing operations despite a cash runway under one quarter.

Micro-X has landed a significant supply agreement with a top US healthcare provider for its Rover Plus mobile X-ray units, while progressing clinical trials and development milestones for its innovative CT imaging products.

Neurotech International reports encouraging Phase I human pharmacokinetic results for its pediatric cannabinoid drug NTI164, alongside published clinical trial data in Rett Syndrome and key regulatory progress in the US and Australia.

Oakajee Corporation has progressed its gold exploration efforts at the Paynes Find project in Western Australia, preparing for drilling in the September quarter while maintaining a solid financial position.

Acrux Limited has secured a decade-long licensing agreement with Servacure to commercialise its FDA-approved Dapsone 5% Gel in Saudi Arabia, marking a strategic step in its global expansion.

EverGreen Lithium Limited has acquired the Leonora Goldfields Project, adding a JORC-compliant inferred gold resource of 63,000 ounces and setting the stage for a targeted drilling campaign to expand and upgrade this resource.

Amplia Therapeutics reports encouraging ACCENT trial results for its FAK inhibitor narmafotinib, including rare complete responses in pancreatic cancer, alongside a $27.5 million capital raise to fund ongoing clinical development.